x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012000
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly430 of human ETEA/UBXD8 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | FAF2 |
| UniProt No. | Q96CS3 |
| Gene ID | 23197 |
| Gene Description | Ubiquitin regulatory X domain-containing protein 8 is a hairpin-anchored endoplasmic reticulum protein involved in ER associated degradation. It influences this process by promoting translocation of misfolded proteins from the ER lumen to the cytoplasm for proteasome-mediated degradation. UBXD8 is a sensor for unsaturated fatty acids. In the absence of fatty acids UBXD8 binds to and targets INSIG1 for degradation, ultimately resulting in activation of SREBP-1., der this condition, UBXD8 also inhibits triglyceride synthesis by blocking the conversion of diacylglycerols into triglycerides., saturated fatty acids trigger UBXD8 polymerization and dissociation of UBXD8/INSIG1 complex, leading to feedback inhibition of SREBP-1. This induces UBXD8 to translocate from the ER to lipid droplets, where it binds to ATGL and inhibits its lipase activity. The complex containing p97 and UBXD8 is reported to promote disassembly of the ribonucleoprotein complex to control mRNA stability. In addition, UBXD8 binds to and promotes degradation of neurofibromin, suggesting a role in regulating Ras activity. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
